946P Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)

Tq, Zhang; Zuo, M-X.; Geng, Z-J.; Huang, Zhongcheng; Li, JB; Ph, Wu; Yk, Gu

doi:10.1016/j.annonc.2021.08.166

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on RECIST 1.1 criteria, the first-line treatment ORR was 44.7% and the DCR was 83.0%, which was similar to the ORR (18.3–58.3%) and DCR (18.3–90.0%) of patients with advanced HCC who had previously received lenvatinib, pembrolizumab plus lenvatinib, and HAIC combined with lenvatinib ( 11 – 13 ). Based on mRECIST criteria, the ORR and DCR of first-line treatment patients were 66.0 and 83.0%, similar to the previous research results of HAIC combined with PD-1 antibody and molecular targeted agent (ORR 40 to 100%, DCR 77.6–100%) ( 9 , 10 , 14 – 16 ). In this study, however, the PFS observed in the first-line treatment group (6.7 months) was significantly worse than that in the previous study (8.8–11.1 months) ( 10 , 15 , 16 ).…”

Section: Discussionsupporting

confidence: 86%

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundThe purpose of the study was to assess the efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) who are undergoing hepatic arterial infusion chemotherapy (HAIC) combined with programmed cell death protein-1 (PD-1) antibody and lenvatinib.MethodsWe retrospectively evaluated 61 patients treated with HAIC combined with PD-1 antibody and lenvatinib at the Second Affiliated Hospital of Nanchang University between September 2020 and January 2022 for advanced HCC. We analyzed tumor response, progression free survival (PFS), and treatment-related adverse events (TRAEs).ResultsThe objective response rate (ORR) was 36.1% (RECIST 1.1)/57.4% (mRECIST) and the disease control rate (DCR) was 82.0%. The overall median PFS was 6.0 months, 6.7 months for first-line treatment, and 4.3 months for second-line treatment. The most common TRAEs were neutropenia (50.8%), abdominal pain (45.9%), and aspartate aminotransferase increase (39.3%).ConclusionHepatic arterial infusion chemotherapy combined with PD-1 antibody and lenvatinib is effective in the treatment of advanced HCC, and the TRAEs are generally controllable.

show abstract

Section: Discussionsupporting

confidence: 86%

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…[4][5][6] Although effective, it should be noted that patients may not tolerate synchronously combined therapies because of the superimposed treatment toxicities related to their different mechanisms (grade 3/4 adverse events: 53.2%-69.2%). 5,7,8 In our study, the HAIC-FO monotherapy caused a low percentage of grade 3/4 adverse events (20.3%) which might encourage more patients to accept a higher dose of chemotherapy. 9 Low toxicity should be a fundamental quality of any effective treatment recommended for the advanced HCC population, especially for those with decompensated liver function and poor physical status.…”

mentioning

confidence: 53%

Reply to O. Sütcüoğlu et al

Lyu¹,

Zhao

2022

JCO

View full text Add to dashboard Cite

Reply to O. S ütc üo glu et alWe appreciate S ütc üo glu et al 1 for their interest in our randomized phase III study that demonstrated the clinical superiority of the arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; HAIC-FO) compared with multikinase tyrosine inhibitor sorafenib in advanced hepatocellular carcinoma (HCC; FOHAIC-1). 2 According to our retrospective study, patients with lung metastases treated with HAIC-FO had shorter survival than those without. 3 S ütc üo glu et al 1 expressed concern regarding this issue in the FOHAIC-1 study, and, therefore, we performed a subgroup analysis comparing the survival of patients with lung metastases between the two groups. After recalculation, we further confirmed that lung metastasis is a poor prognosis factor in the HAIC-FO arm (hazard ratio, 1.622; 95% CI, 1.017 to 2.586; P 5 .042). HAIC-FO presented better and more stable responses than sorafenib as both progression-free and intrahepatic progression-free survival were longer in patients with lung metastases. Nevertheless, the overall survival between groups was not statistically different (Table 1). As this is a post hoc subgroup analysis, the results should be interpreted with caution.

show abstract

“…The reason may be that the patients’ average liver tumor diameter in the previous study was smaller compared to this study (6.1 ± 2.5 vs. 9.6 ± 4.8 cm) ( 27 ). In the TRIPLET study ( 28 ), HCC patients in BCLC stage C who received hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab had an ORR and DCR of 61.54% and 92.3%, respectively. These results were better than the data obtained in this study, and the reason may be that all patients in the TRIPLET study received no previous treatment (in this study, patients with BCLC C stage HCC were previously treated with locoregional therapy).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis

et al. 2022

View full text Add to dashboard Cite

PurposeTo compare the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib and immune checkpoint inhibitors (T+S+ICIs) and TACE plus sorafenib (T+S) when treating patients with advanced hepatocellular carcinoma (HCC) who have previously received locoregional treatment.Materials and methodsA retrospective analysis was performed on the patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC from May 2019 to December 2020. These patients were treated with locoregional therapy and showed radiographic progression after the treatment. Patients received either T+S+ICIs or T+S. The outcomes, including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety, were compared. The propensity score matching (PSM) methodology was used to reduce the influence of confounding factors on the outcomes.ResultsForty-three patients were included in the T+S group and 33 in the T+S+ICI group. After PSM (n = 29 in each group), patients who received T+S+ICIs had a higher DCR (82.8% vs. 58.6%, p = 0.043), longer median PFS (6.9 vs. 3.8 months, p = 0.003), and longer median OS (12.3 vs. 6.3 months, p = 0.008) than those who underwent T+S. Eastern Cooperative Oncology Group performance status was an independent predictor of PFS, and age was an independent predictor of OS. The incidence of treatment-related adverse events in T+S+ICIs was well controlled.ConclusionsCompared with TACE combined with sorafenib, TACE combined with sorafenib plus ICIs is a potentially safe and effective treatment regimen for patients with advanced HCC who previously received locoregional treatment.

show abstract

946P Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)

Cited by 6 publications

References 0 publications

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

Reply to O. Sütcüoğlu et al

Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis

Contact Info

Product

Resources

About